Illumina acquires Fluent BioSciences to accelerate single-cell analysis and discovery to a broader customer base
Illumina (NASDAQ: ILMN) announced its acquisition of Fluent BioSciences, effective July 9, 2024. Fluent BioSciences specializes in highly differentiated single-cell analysis technology. This acquisition enhances Illumina's multiomics capabilities by integrating Fluent's innovative PIPseq™ V technology, which offers scalable and accessible single-cell analysis without costly instrumentation. Illumina aims to deliver comprehensive multiomics solutions, fostering faster and more economical research. The acquisition is funded with cash on hand, and Fluent's team will join Illumina to develop end-to-end solutions for single-cell analysis.
- Illumina acquires Fluent BioSciences, enhancing its multiomics capabilities.
- Integration of PIPseq™ V allows scalable single-cell analysis from 100 to 1 million cells.
- Fluent's technology removes barriers and reduces costs of single-cell analysis.
- Acquisition funds were provided by Illumina's cash on hand, avoiding shareholder dilution.
- The financial terms of the acquisition have not been disclosed, potentially causing uncertainty.
Illumina's acquisition of Fluent BioSciences represents a strategic move into the burgeoning single-cell analysis market. This acquisition not only strengthens Illumina's multiomics capabilities but also positions the company to tap into a growing segment of biological research. Financially, this should enhance Illumina's revenue streams by expanding its product portfolio with more diverse and scalable solutions.
From an investment perspective, eliminating the need for complex and costly equipment could attract a broader range of customers, thus potentially increasing sales volume. The integration of Fluent's PIPseq™ V technology into Illumina's offerings could also lead to new revenue opportunities through both existing and newly developed products. However, investors should consider the costs associated with the acquisition and integration, even though it was funded with cash on hand.
In the short term, investors might see some fluctuations in Illumina's stock price as the market digests this news. However, in the long term, this acquisition is likely to be beneficial, provided Illumina successfully integrates Fluent's technologies and capitalizes on the expanded market opportunities.
Single-cell analysis is an emerging field with high growth potential and Illumina's acquisition of Fluent BioSciences places it at the forefront of this market. The unique selling point of Fluent's technology is its elimination of complex and expensive instrumentation, making it accessible to a broader audience. This accessibility could democratize single-cell analysis, expanding its use from large, well-funded institutions to smaller labs and even potentially clinical settings.
This acquisition can potentially disrupt the current market dynamics by lowering the barriers to entry for single-cell research. As more researchers gain access to this technology, the demand for related consumables and services is likely to increase, benefiting Illumina's broader business. Additionally, the scalability of Fluent’s PIPseq™ V, capable of processing a range from 100 to 1 million cells, makes it versatile for various research needs, further broadening its market appeal.
For retail investors, this move signals Illumina's commitment to innovation and market expansion, which is a positive indicator for long-term growth prospects. However, the success of this integration and the market's acceptance of this new technology will be critical factors to watch.
From a research perspective, the acquisition of Fluent BioSciences by Illumina could be a game-changer in the field of multiomics and single-cell analysis. Fluent's PIPseq™ V technology, which can detect cell types often missed by current methods, offers significant advantages for scientific discovery. By removing the need for complex instrumentation, this technology makes high-quality single-cell analysis more accessible, which can catalyze new research and potentially lead to groundbreaking discoveries in areas such as cancer, neurology and immunology.
The ability to perform assays at the point of sample collection is another notable innovation. This capability can improve the accuracy and reliability of single-cell analysis, offering researchers more precise and actionable data. Integration with Illumina's existing sequencing and informatics solutions will provide researchers with a comprehensive toolset, facilitating faster and more economical advancements in multiomics research.
For investors, the scientific promise of this acquisition can translate into significant long-term value as new research breakthroughs lead to new applications and demand for Illumina's solutions. However, the true impact will depend on how effectively Illumina can leverage Fluent’s technology to drive innovation and meet evolving research needs.
Accessible, highly scalable single-cell technology expands Illumina's multiomics capabilities
"The addition of Fluent BioSciences to Illumina will provide significant and new capabilities to our customers in a key growth area and advances our multiomics growth strategy," said Steven Barnard, chief technology officer of Illumina. "Single-cell research opens doors to new areas of discovery, and Fluent's innovative, accessible, and flexible single-cell method will accelerate our ability to deliver full multiomics solutions for our customers."
Fluent's single-cell analysis technology eliminates the need for complex, expensive instrumentation and microfluidic consumables. This novel approach removes many of the barriers and limitations of current methods, making single-cell analysis accessible for a broader set of customers, and catalyzing new experiments enabled by the ability to perform that assay at the point of sample collection. Fluent's latest release, PIPseq™ V, delivers exceptional performance, with the ability to detect cell types often missed with current methods, and the highest scalability, capable of processing a range from 100 cells up to 1 million.
Fluent's unique technology combined with Illumina's leading sequencing and informatics solutions including Partek Flow, which enables single-cell multiomic analysis, will provide customers with a complete solution and single point of support so that researchers can advance discovery faster and more economically.
The Fluent team will join Illumina, and PIPseq V will be integrated into Illumina's product portfolio. The company plans to build on Fluent's technology to develop full end-to-end solutions for single-cell analysis.
Illumina will remain an open NGS platform and is committed to maintaining and supporting its existing single-cell partnerships. "Our goal is to continue to develop the sequencing eco-system and support the best multiomics solutions like single-cell analysis," Barnard said. "We want customers to have the flexibility to adopt the tools that best fit their needs."
The acquisition closed on July 9, 2024, and has been funded with cash on hand.
Use of forward-looking statements
This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding our expectations for the utility and success of Fluent's products and the integration of Fluent's technology and products into our portfolio. These forward-looking statements are based on our expectations as of the date of this release and may differ materially from actual future events or results. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are (i) our ability to successfully integrate Fluent into our existing operations and Fluent's technology and products into our portfolio; (ii) our ability to sell Fluent's products and further develop Fluent's technology; (iii) our ability to successfully manage partner and customer relationships in the single-cell market; (iv) our ability to manufacture robust instrumentation and consumables, including Fluent's products; (v) the future conduct and growth of the business and the markets in which we operate, including the single-cell market; and (vi) challenges inherent in developing, manufacturing, and launching new products and services, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Salli Schwartz
858-291-6421
IR@illumina.com
Media:
Bonny Fowler
Samantha Beal
PR@illumina.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-acquires-fluent-biosciences-to-accelerate-single-cell-analysis-and-discovery-to-a-broader-customer-base-302192516.html
SOURCE Illumina, Inc.
FAQ
What is the significance of Illumina acquiring Fluent BioSciences?
When did Illumina acquire Fluent BioSciences?
How does Fluent BioSciences' technology benefit Illumina?
What is PIPseq™ V technology?
